Delivery Order SPE2DB22D1106-SPE2DB25FFEB2
- Not listed
- This is a $1,797.13 delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of AZSTARYS 52.3 MG-10.4 MG CAP 100S, a pharmaceutical product, with a performance period ending on May 22, 2025. The contract is a firm fixed-price arrangement and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite...
- This is a $1,304.01 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of AZSTARYS 39.2 MG-7.8 MG CAP 100S, a pharmaceutical product, with a performance period ending on February 13, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,284.14, is for the delivery of AZSTARYS CAPS 39.2MG/7.8MG, a pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of March 12, 2025. The contract has no set-aside designation, indicating open...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $2,277.09, is for the provision of AZSTARYS CAPS 52.3MG/10.4MG, a pharmaceutical product. The award has an ultimate completion date of January 7, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,779.20 fixed-price delivery order is for AZSTARYS CAPS 26.1MG/5.2MG, a pharmaceutical product, with a performance period ending on May 19, 2025. The contract is not set aside and represents an open competition award. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of AZSTARYS 39.2 MG-7.8 MG CAP 100S, a pharmaceutical product. The total ceiling value of the contract is $1,630.88, with a period of performance through June 11, 2025. The contract is a firm-fixed-price delivery order, with no set-aside designation, indicating open...
- This is a firm fixed-price delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Medical Supply Chain. The $2,959.88 contract is for the delivery of the medication AZSTARYS CAPS 39.2MG/7.8MG. This order is part of Amerisourcebergen's $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated as SPE2DX, which runs through December 2026. This IDC serves as a comprehensive global...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of AZSTARYS CAPS 39.2MG/7.8MG, a pharmaceutical product. The contract has a ceiling value of $1,537.26 and a period of performance through May 8, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 that AmerisourceBergen holds with the DLA Troop Support Medical, which...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of AZSTARYS 39.2 MG-7.8 MG CAP 100S, a pharmaceutical product. The contract has a firm fixed price of $2,941.40 and a completion date of May 1, 2025. It is not a set-aside contract, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an award value of $2,148.68 and is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 that runs through November 2026. The IDC serves as a primary vehicle for AmerisourceBergen to provide a comprehensive range of pharmaceutical products and medical supplies, including...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFEB2Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,782.29 to AmerisourceBergen Drug Corp for AZSTARYS 39.2 mg-7.8 mg capsules (100-count) on August 19, 2025, with completion scheduled for August 20, 2025. This contract represents a firm fixed price delivery order with no set-aside designation, issued competitively under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion pharmaceutical supply vehicle running through December 2026. The place of performance is located in Conshohocken, Pennsylvania, AmerisourceBergen's corporate headquarters. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order is one of numerous transactions through which the company supplies a wide spectrum of pharmaceutical products and medical commodities to the Defense Health Agency and other federal healthcare customers. The underlying IDC vehicle enables flexible, global pharmaceutical support across multiple therapeutic domains, with the DLA planning to establish next-generation Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards in the coming years.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.8k | 8/19/25 |